Cricket News England vs India, 3rd T20I Preview: Virat Kohli and Co eyes to clinch series at Bristol

Tag: 上海夜网GQ

first_imgNew Delhi: After losing second T20I game to England at Cardiff, Virat Kohli and Co will enter The County Ground at Bristol with a mind-set to clinch the three-match T20 series.In the last match, the batting line up failed and team only put 147 runs on board and the star bowler of the first T20 match, Kuldeep Yadav could not pick up even a single wicket.Now, it’s a must-win game for India and the Virat Kohli brigade will look to end the series with a winning momentum and enter ODI series with a positive mind-set.England changed their batting line up a bit which helped them perform well at the Cardiff. Joe Root was sent up at number four, with skipper Eoin Morgan dropping down to allow the former more time at the crease. If team India had won the second T20 match, then it would have given Virat Kohli a chance to experiment Manish Pandey, Siddarth Kaul, Krunal Pandya and Deepak Chahar waiting in the wingsMatch Predictions – Ben Stokes is making a return in the third match and will also provide another seam-bowling option, and thus it remains to be seen if Moeen Ali will return to the eleven.  For all the Latest Sports News News, Cricket News News, Download News Nation Android and iOS Mobile Apps.last_img read more


Tag: 上海夜网GQ

first_imgMORE COVERAGEGraphical breakdown of Syracuse’s 80-75 loss at PittsburghWhat we learned after Syracuse’s 80-75 loss at PittsburghLimited minutes for Thompson and Battle sting Syracuse in 80-75 loss to PittsburghTyler Lydon held to only 8 points in Syracuse’s 80-75 loss at PittsburghGallery: Syracuse loses to Pittsburgh, 80-75 Comments AdvertisementThis is placeholder text Published on February 11, 2017 at 7:23 pm Following Syracuse’s (16-10, 8-5 Atlantic Coast) 80-75 loss at Pittsburgh (14-11, 3-9), our beat writers Connor Grossman and Paul Schwedelson discuss where SU stands. And with five games left, what does Syracuse have to do from here? Facebook Twitter Google+last_img


Tag: 上海夜网GQ

first_imgPush Toward Arbitration Model To Address High Drug Prices Leaves Progressive Democrats Unsatisfied The idea behind arbitration is to have a third party help decide the price the government would pay for a number of high-priced drugs, but progressive Democrats say that falls short of what would be effective. “If we did come to an arbitration model, I think there would be a large ‘womp, womp,’” Rep. Mark Pocan (D-Wis.). The discussion of Medicare’s ability to negotiate prices came as a multitude of bipartisan bills addressing high drug prices moved forward in the House. During a meeting, the Congressional Progressive Caucus urged House Energy and Commerce Committee Chairman Frank Pallone Jr. (D-N.J.) and House Ways and Means Committee Chairman Richard Neal (D-Mass.) to support a far-reaching drug pricing bill that would allow the government to strip drug companies of their monopolies if they refuse to sell drugs at a reasonable price. The progressives also pushed back on a competing proposal under discussion that would allow an outside arbiter to help set drug prices, warning that the idea would be too weak. (Sullivan, 4/30) Politico Pro: House Judiciary Approves 4 Bills Boosting Generics CQ: House Advances Drug Price Agenda, But Medicare Issues Unsettled Modern Healthcare: House Lawmakers Bash Trump’s Medicare Drug Pricing Efforts Stat: Progressives Warn Democratic Leaders They Must Be Bolder On Drug Pricing The Hill: Progressives Push House Chairmen To Go Bolder On Drug Pricing  center_img This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription. Progressive lawmakers are increasingly warning that they would forcefully oppose any effort to set up a system of arbitration to help lower drug prices, a model that would fall short of their demands to allow the federal government to negotiate with drug companies. It’s an idea that has the implicit backing of House Speaker Nancy Pelosi (D-Calif.), whose top health policy aide has been focused on the proposal in talks with other experts. The speaker’s backing of any eventually legislation could put it on the fast track for congressional action, though no bill on the issue has yet been introduced in Congress. (Florko, 4/30) Republicans and Democrats on the House Energy & Commerce Committee’s health subcommittee alleged that the Trump administration’s efforts threaten patient access to needed drugs. Step therapy requires a patient to try a cheaper drug before a more expensive drug and prior authorization requires insurance to approve a prescription before it’s issued. “It is not defensible in my view,” said Rep. Anna Eshoo (D-Calif.), who chairs the subcommittee. “I don’t know who supports this thing.” (King, 4/30) The House Judiciary Committee this afternoon approved by voice vote four bipartisan bills to boost generic drug competition. The most high-profile bill passed by the committee was the CREATES Act, H.R. 965 (116), which penalizes drugmakers that withhold samples from generic rivals. The bill could now move to the House floor for a vote. (Owermohle, 4/30) A House committee on Tuesday approved bills to address high drug prices as chairmen of two other committees overseeing Democrats’ drug plans met with the party’s progressive wing to discuss a big unsettled piece of their agenda: Medicare price negotiation. Even as committees have moved forward on bipartisan drug price bills that are supposed to be on the House floor in May, the party still hasn’t finalized how to approach one of its key campaign promises, direct Medicare negotiation with drug manufacturers. (Siddons, 4/30) last_img read more